Factors Associated with Decision Making in the Second-Line Treatment of Patients with Advanced/Metastatic Gastrointestinal Cancers
Released On
December 21, 2023
Expires On
November 28, 2024
Media Type
Internet
Completion Time
60 minutes
Specialty
Gastrointestinal Cancers, Oncology
Topic(s)
Advanced/Metastatic Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
This activity is provided by Med Learning Group.
This activity is co-provided by AMEDCO.
Nursing learners, view this Learner Notification prior to starting this activity
This activity is supported by a independent medical education grant from Lilly.
Credit Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
- Nurses — maximum of 1.0 ANCC contact hour
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity is designed to educate community-based oncologists, oncology nurses, and other healthcare providers involved in the care of patients with advanced/metastatic gastric cancer and gastroesophageal junction adenocarcinoma.
Program Overview
This enduring educational activity focuses on the care of patients with advanced/metastatic gastric cancer and gastroesophageal junction adenocarcinoma. The program aims to help healthcare professionals improve their ability to evaluate which patient populations may benefit from anti-angiogenic therapy as a second-line treatment for advanced or metastatic gastric and gastroesophageal junction (GEJ) cancers, and to select appropriate second- and subsequent-line therapy based on clinical practice guidelines and the latest clinical trial findings.
Educational Objectives
Upon the completion of this program, attendees should be able to:
- Evaluate which patient populations may benefit from anti-angiogenic therapy as a second-line treatment for advanced or metastatic gastric and gastroesophageal junction (GEJ) cancers
- Select appropriate second- and subsequent-line therapy for the management of gastric/GEJ cancers
- Assess clinical trials findings in patients who could benefit from anti-angiogenic treatment for advanced or metastatic gastric and gastroesophageal junction (GEJ) cancers
- Apply clinical practice guidelines for second treatment in patients with advanced and metastatic gastrointestinal cancers to maximize patient outcomes through proper sequencing of therapy
Faculty
Richard F. Dunne, MD, MS
PROGRAM CHAIR
Associate Professor of Medicine
Leader, Gastrointestinal Cancer Unit and Clinical Research Program
Wilmot Cancer Institute
University of Rochester Medical Center
Rochester, NY
Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
Physician Credit Designation Statement
Med Learning Group designates this virtually live activity for a maximum of 1.0 AMA PRA Category 1 Credit™ Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Nurses (ANCC) Credit Designation
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.
Disclosure Policy Statement
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
Disclosure of Relevant Financial Relationship(s)
- Richard F. Dunne, MD
- Consultant: Exelixis, Toray Industries, Helsinn Healthcare, and Merck
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Nicole Longo, DO, FACOI, VP of Med/Sci Services & Learner Engagement for Med Learning Group has nothing to disclose.
Chimene Richa, MD, Medical Director of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
Lauren Bartunek, Program Manager for Med Learning Group, has nothing to disclose.
Heather Gee, Program Coordinator for Med Learning Group, has nothing to disclose.
Method of Participation
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
Disclaimer
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: https://www.medlearninggroup.com/privacy-policy/
Americans with Disabilities Act
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
Content - Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
